Cassava Sciences, Inc. (NASDAQ:SAVA) Stock Holdings Lifted by Deutsche Bank AG

Deutsche Bank AG increased its position in shares of Cassava Sciences, Inc. (NASDAQ:SAVA) by 42.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,571 shares of the company’s stock after acquiring an additional 10,940 shares during the quarter. Deutsche Bank AG owned 0.08% of Cassava Sciences worth $86,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Apollon Wealth Management LLC purchased a new position in Cassava Sciences during the 4th quarter worth approximately $73,000. Raymond James Financial Inc. acquired a new stake in shares of Cassava Sciences in the fourth quarter worth $147,000. Marshall Wace LLP purchased a new position in shares of Cassava Sciences during the fourth quarter valued at $50,000. Russell Investments Group Ltd. raised its position in Cassava Sciences by 5,905.4% during the fourth quarter. Russell Investments Group Ltd. now owns 22,220 shares of the company’s stock valued at $52,000 after buying an additional 21,850 shares during the period. Finally, Hsbc Holdings PLC acquired a new position in Cassava Sciences during the fourth quarter valued at $34,000. Hedge funds and other institutional investors own 38.05% of the company’s stock.

Cassava Sciences Stock Performance

Shares of SAVA opened at $2.16 on Wednesday. Cassava Sciences, Inc. has a 52 week low of $1.15 and a 52 week high of $42.20. The company has a market capitalization of $104.35 million, a PE ratio of -1.57 and a beta of -2.00. The company’s 50 day moving average price is $1.66 and its 200 day moving average price is $3.21.

Cassava Sciences (NASDAQ:SAVA) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.48) earnings per share for the quarter. On average, equities analysts forecast that Cassava Sciences, Inc. will post -3.97 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “neutral” rating and set a $2.00 price objective on shares of Cassava Sciences in a research report on Tuesday, March 25th.

Cassava Sciences Profile

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.